Literature DB >> 2293788

Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients.

J L Martinot1, P Peron-Magnan, J D Huret, B Mazoyer, J C Baron, J P Boulenger, C Loc'h, B Maziere, V Caillard, H Loo.   

Abstract

Striatal D2 dopaminergic receptors of 12 drug-free schizophrenic patients and 12 normal subjects were investigated with positron emission tomography and [76Br]bromospiperone. Patients were classified according to DSM-III criteria, and their clinical symptoms were rated according to Andreasen's negative and positive symptom scales. The ratio of striatal to cerebellar radioactivity was taken as an index of striatal D2 dopamine receptor density. There was no significant difference between the control subjects and the overall schizophrenic group and no significant relationship between this index and the symptom ratings. However, state-dependent variables could partly account for the striatal D2 receptor density variability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293788     DOI: 10.1176/ajp.147.1.44

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

1.  Understanding schizophrenia.

Authors:  L S Pilowsky
Journal:  BMJ       Date:  1992-08-08

2.  SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain.

Authors:  J Kornhuber; T Brücke; P Angelberger; S Asenbaum; I Podreka
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 3.  Traditional receptor theory and its application to neuroreceptor measurements in functional imaging.

Authors:  R W Kerwin; L S Pilowsky
Journal:  Eur J Nucl Med       Date:  1995-07

4.  Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

Authors:  C J Bench; A A Lammertsma; R J Dolan; P M Grasby; S J Warrington; K Gunn; M Cuddigan; D J Turton; S Osman; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 5.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 6.  Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia.

Authors:  Urs Meyer; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2009-03-11       Impact factor: 4.530

Review 7.  The dopamine hypothesis of schizophrenia: version III--the final common pathway.

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

Review 8.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

9.  Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims.

Authors:  J Ruiz; A M Gabilondo; J J Meana; J A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.

Authors:  G F Busatto; L S Pilowsky; D C Costa; P J Ell; N P Verhoeff; R W Kerwin
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.